A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Asthenia
- Focus Therapeutic Use
- Sponsors Longeveron
- 14 Dec 2018 Planned number of patients changed from 120 to 150.
- 14 Dec 2018 Planned End Date changed from 28 Sep 2019 to 28 Sep 2020.
- 14 Dec 2018 Planned primary completion date changed from 2 Jun 2019 to 30 Jun 2020.